For Healthcare Professionals Outside the US

Make a lasting impression on chronic transfusional iron overload

EXJADE® (deferasirox) film-coated tablets provides efficacy and safety in a convenient once-daily oral tablet

Simplified administration
Proven Efficacy
Improved Adherence

Indications

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 mL/kg/month of packed red blood cells) in patients with beta thalassemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:

  • In pediatric patients with beta thalassemia major with iron overload due to frequent blood transfusions (≥7 mL/kg/month of packed red blood cells) aged 2 to 5 years
  • In adult and pediatric patients with beta thalassemia major with iron overload due to infrequent blood transfusions (<7 mL/kg/month of packed red blood cells) aged 2 years and older
  • In adult and pediatric patients with other anemias aged 2 years and older

EXJADE is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with nontransfusion-dependent thalassemia syndromes aged 10 years and older.

Reference

Please note: In some countries, EXJADE film-coated tablets is available as JADENU® (deferasirox) tablets.